Literature DB >> 27677739

Kinase inhibitor ibrutinib to prevent cytokine-release syndrome after anti-CD19 chimeric antigen receptor T cells for B-cell neoplasms.

M Ruella1,2,3, S S Kenderian1,2,3,4, O Shestova1,2,3, M Klichinsky1,2,5, J J Melenhorst1,2,3, M A Wasik2,3, S F Lacey1,2,3, C H June1,2,3,6, S Gill1,2,4,7.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27677739     DOI： 10.1038/leu.2016.262

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  14 in total

1.  Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity.

Authors:  Holbrook E Kohrt; Idit Sagiv-Barfi; Sarwish Rafiq; Sarah E M Herman; Jonathon P Butchar; Carolyn Cheney; Xiaoli Zhang; Joseph J Buggy; Natarajan Muthusamy; Ronald Levy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

2.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

3.  Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK.

Authors:  Idit Sagiv-Barfi; Holbrook E K Kohrt; Debra K Czerwinski; Patrick P Ng; Betty Y Chang; Ronald Levy
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

4.  Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.

Authors:  Marco L Davila; Isabelle Riviere; Xiuyan Wang; Shirley Bartido; Jae Park; Kevin Curran; Stephen S Chung; Jolanta Stefanski; Oriana Borquez-Ojeda; Malgorzata Olszewska; Jinrong Qu; Teresa Wasielewska; Qing He; Mitsu Fink; Himaly Shinglot; Maher Youssif; Mark Satter; Yongzeng Wang; James Hosey; Hilda Quintanilla; Elizabeth Halton; Yvette Bernal; Diana C G Bouhassira; Maria E Arcila; Mithat Gonen; Gail J Roboz; Peter Maslak; Dan Douer; Mark G Frattini; Sergio Giralt; Michel Sadelain; Renier Brentjens
Journal:  Sci Transl Med       Date:  2014-02-19       Impact factor: 17.956

5.  Current concepts in the diagnosis and management of cytokine release syndrome.

Authors:  Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall
Journal:  Blood       Date:  2014-05-29       Impact factor: 22.113

6.  The Addition of the BTK Inhibitor Ibrutinib to Anti-CD19 Chimeric Antigen Receptor T Cells (CART19) Improves Responses against Mantle Cell Lymphoma.

Authors:  Marco Ruella; Saad S Kenderian; Olga Shestova; Joseph A Fraietta; Sohail Qayyum; Qian Zhang; Marcela V Maus; Xiaobin Liu; Selene Nunez-Cruz; Michael Klichinsky; Omkar U Kawalekar; Michael Milone; Simon F Lacey; Anthony Mato; Stephen J Schuster; Michael Kalos; Carl H June; Saar Gill; Mariusz A Wasik
Journal:  Clin Cancer Res       Date:  2016-01-27       Impact factor: 12.531

7.  Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.

Authors:  Joseph A Fraietta; Kyle A Beckwith; Prachi R Patel; Marco Ruella; Zhaohui Zheng; David M Barrett; Simon F Lacey; Jan Joseph Melenhorst; Shannon E McGettigan; Danielle R Cook; Changfeng Zhang; Jun Xu; Priscilla Do; Jessica Hulitt; Sagar B Kudchodkar; Alexandria P Cogdill; Saar Gill; David L Porter; Jennifer A Woyach; Meixiao Long; Amy J Johnson; Kami Maddocks; Natarajan Muthusamy; Bruce L Levine; Carl H June; John C Byrd; Marcela V Maus
Journal:  Blood       Date:  2016-01-26       Impact factor: 22.113

8.  Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.

Authors:  David T Teachey; Simon F Lacey; Pamela A Shaw; J Joseph Melenhorst; Shannon L Maude; Noelle Frey; Edward Pequignot; Vanessa E Gonzalez; Fang Chen; Jeffrey Finklestein; David M Barrett; Scott L Weiss; Julie C Fitzgerald; Robert A Berg; Richard Aplenc; Colleen Callahan; Susan R Rheingold; Zhaohui Zheng; Stefan Rose-John; Jason C White; Farzana Nazimuddin; Gerald Wertheim; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  Cancer Discov       Date:  2016-04-13       Impact factor: 39.397

9.  Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.

Authors:  Michael L Wang; Simon Rule; Peter Martin; Andre Goy; Rebecca Auer; Brad S Kahl; Wojciech Jurczak; Ranjana H Advani; Jorge E Romaguera; Michael E Williams; Jacqueline C Barrientos; Ewa Chmielowska; John Radford; Stephan Stilgenbauer; Martin Dreyling; Wieslaw Wiktor Jedrzejczak; Peter Johnson; Stephen E Spurgeon; Lei Li; Liang Zhang; Kate Newberry; Zhishuo Ou; Nancy Cheng; Bingliang Fang; Jesse McGreivy; Fong Clow; Joseph J Buggy; Betty Y Chang; Darrin M Beaupre; Lori A Kunkel; Kristie A Blum
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245

10.  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.

Authors:  John C Byrd; Richard R Furman; Steven E Coutre; Ian W Flinn; Jan A Burger; Kristie A Blum; Barbara Grant; Jeff P Sharman; Morton Coleman; William G Wierda; Jeffrey A Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Juthamas Sukbuntherng; Betty Y Chang; Fong Clow; Eric Hedrick; Joseph J Buggy; Danelle F James; Susan O'Brien
Journal:  N Engl J Med       Date:  2013-06-19       Impact factor: 91.245
View more
  46 in total

1.  Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels.

Authors:  Juliana Velez Lujan; Paula A Lengerke-Diaz; Chaja Jacobs; Eider F Moreno-Cortes; Cesar A Ramirez-Segura; Michael Y Choi; Colin McCarthy; Alaina Heinen; Thomas J Kipps; Januario E Castro
Journal:  Haematologica       Date:  2019-05-02       Impact factor: 9.941

2.  The specific Bruton tyrosine kinase inhibitor acalabrutinib (ACP-196) shows favorable in vitro activity against chronic lymphocytic leukemia B cells with CD20 antibodies.

Authors:  Josée Golay; Greta Ubiali; Martino Introna
Journal:  Haematologica       Date:  2017-06-22       Impact factor: 9.941

3.  Predicting Dangerous Rides in CAR T Cells: Bridging the Gap between Mice and Humans.

Authors:  Marco Ruella; Carl H June
Journal:  Mol Ther       Date:  2018-05-19       Impact factor: 11.454

Review 4.  The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.

Authors:  Peter Braendstrup; Bruce L Levine; Marco Ruella
Journal:  Cytotherapy       Date:  2020-02-01       Impact factor: 5.414

5.  The Bruton's tyrosine kinase inhibitor ibrutinib abrogates bispecific antibody-mediated T-cell cytotoxicity.

Authors:  Colin D Godwin; Olivia M Bates; Eliotte E Garling; Mary E Beddoe; George S Laszlo; Roland B Walter
Journal:  Br J Haematol       Date:  2020-02-04       Impact factor: 6.998

6.  Weathering the storm: Improving therapeutic interventions for cytokine storm syndromes by targeting disease pathogenesis.

Authors:  Lehn K Weaver; Edward M Behrens
Journal:  Curr Treatm Opt Rheumatol       Date:  2017-02-07

Review 7.  Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.

Authors:  Zohreh Sadat Badieyan; Sayed Shahabuddin Hoseini
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2018-02-09       Impact factor: 4.291

8.  GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts.

Authors:  Rosalie M Sterner; Reona Sakemura; Michelle J Cox; Nan Yang; Roman H Khadka; Cynthia L Forsman; Michael J Hansen; Fang Jin; Katayoun Ayasoufi; Mehrdad Hefazi; Kendall J Schick; Denise K Walters; Omar Ahmed; Dale Chappell; Tarek Sahmoud; Cameron Durrant; Wendy K Nevala; Mrinal M Patnaik; Larry R Pease; Karen E Hedin; Neil E Kay; Aaron J Johnson; Saad S Kenderian
Journal:  Blood       Date:  2018-11-21       Impact factor: 22.113

Review 9.  C(h)AR-ting a new course in incurable lymphomas: CAR T cells for mantle cell and follicular lymphomas.

Authors:  Caron A Jacobson; Marcela V Maus
Journal:  Blood Adv       Date:  2020-11-24

Review 10.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.